FDA Program Promises to End Years of Ketamine Shortages for Mental Health Clinics
Phlow Corp. has been selected for the FDA’s inaugural Commissioner’s National Priority Voucher Pilot Program to manufacture ketamine’s active pharmaceutical ingredient domestically. This development could transform operations for thousands of ketamine clinics treating depression and mental health conditions across America.
Do you work in the ketamine industry? We launched the Healing Health Alliance, which is the first national provider network and GPO (Group Purchasing Organization) exclusively for ketamine practitioners and clinic owners. We will bring you significant cost savings and revenue generating opportunities. There’s no cost or obligation and you can join now!
| Key Takeaway | Impact |
|---|---|
| Domestic ketamine API production | Ends reliance on foreign suppliers |
| Seven year shortage resolution | Stable supply from February 2018 shortage |
| Accelerated FDA review (1-2 months) | Faster market availability |
| End to end US supply chain | Improved reliability and transparency |
| Strategic pharmaceutical reserves | Buffer against future disruptions |
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
A Solution Seven Years in the Making
The United States currently has no domestic ketamine API suppliers, creating vulnerability in a critical medication supply chain. Mental health clinics have struggled through persistent shortages that forced them to ration treatments, turn away patients, or suspend services entirely. The most recent shortage lasted from February 2018 through August 2025, affecting both civilian and military medicine.
For ketamine clinics providing IV and IM treatments for depression, PTSD, and other mental health conditions, supply uncertainty has been a constant operational challenge. Many practitioners have experienced the frustration of canceling patient appointments or scrambling to locate alternative suppliers during critical treatment windows.
Rebuilding Pharmaceutical Independence
Phlow’s project, developed in partnership with the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, aims to establish a complete domestic supply chain from raw materials to finished dosage forms. This represents more than manufacturing capability. It creates infrastructure for sustained, predictable access to a medication that has become essential in modern psychiatric care.
The voucher program accelerates regulatory review timelines, potentially bringing domestic production online faster than traditional pathways would allow. Standard drug reviews typically take 10 to 12 months, but the national priority voucher could compress this timeline to one or two months.
Mental health providers offering ketamine therapy should see stabilized pricing and consistent availability once domestic production reaches scale. Clinics will gain the ability to plan treatment programs without factoring supply disruptions into their operational models, potentially expanding access to patients who have exhausted other treatment options.
